Clinical Trial Search

Primary: Change From Baseline in Personal and Social Performance (PSP) Scale Score at Week 52 — 50.65; 58.71; 5.35; 5.96 units on a scale — p=0.8595

Primary: Double-blind: Percentage of Participants Who Experienced Relapse — 15.2; 33.5; 11.5; 32.9 percentage of participants — p=<0.001

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26 — 68.9; 28.1 Units on a scale

Primary: Measurement of Schizophrenia Symptoms: Positive and Negative Syndrome Scale (PANSS) Total Score — 87.57; 88.74; 85.88; 91.68 scores on a scale

Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 13 or Early Discontinuation — 83.5; 85.7; 6.9; -3.1 units on a scale…

Primary: Change in Non-HDL Cholesterol Level for Patients Assigned to Stay and Patients Assigned to Switch Over 24 Weeks — -20.2; -10.8 mg/dL non-HDL cholesterol

Primary: Change in Cognition and Psychopathology Disorders as Measured on the MATRICS Consensus Cognitive Battery (MCCB) — 14.1; 14.3 units on a scale

Primary: Time to Relapse of Psychotic Symptoms During 6 Weeks — 23.8; 16.9; 17.3 days

Primary: Time to Relapse or an Impending Relapse — 0; 3; 1; 14 relapses

Primary: Change From Baseline in Days Homeless Out of the Previous 6 Months as Measured at 25 Weeks — 6.50; 9.85 days

Primary: Baseline Positive and Negative Symptoms of Schizophrenia (PANSS) Total Score — 91.6; 95.9; 92.7 points on a scale

Primary: Changes in Positive Schizophrenia Symptoms — 3.21; 3.30; 3.04; 2.89 units on a scale — p=.30

Primary: Loss of Effect Over Time — 7; 15; 6; 3 Participants

Primary: Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) — 87.30; 87.30; 88.46; 89.23 units on a scale — p=< .05

Primary: Mean Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 — 99.38; 98.54; 100.53; 100.03 Units on a scale — p=0.849

Primary: Positive and Negative Symptoms of Schizophrenia (PANSS) Total Score at Baseline. — 91.7; 92.3 points on a scale — p=0.774

Primary: Number of Participants With Independent Adjudication Committee (IAC) Adjudicated Event of Exacerbation of Disease (EEDS) — 25; 29; 87; 88 Participants — p=0.746

Primary: Average Over Time of Intensity of Cannabis Use (Used to Evaluate Treatment Efficacy) — 0.02; 4.56 Joints per week — p=.088

Primary: Number of Participants Demonstrating Improvement in Substance Use — 3; 3 participants

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 5; 4; 70; 35 participants

Primary: Number of Participants With Relapse — 22; 23 Participants — p=0.59

Primary: Onset of Psychosis — 10; 14 percentage of sample converting

Primary: Change in Persistent Positive Symptoms — 13; 14; 14; 14 units on a scale

Primary: Adverse Events — 98; 10; 16 participants

Primary: Change in Positive Symptoms by Treatment Assignment — 2.222; 1.400; 1.60; 1.00 units on a scale

Primary: QTcB Change — 416.50; 416.41; 418.39; 423.27 ms

Primary: Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) — 6.7; 0.9; 3.9; 5.9 T scores — p=<0.03

Primary: Mean Change From Baseline to 52 Weeks in Body Mass Index (BMI) for All Participants — 3.64; 2.83 kilograms per meter squared (kg/m^2) — p=0.150

Primary: Incidence of Adverse Events — 314 Participants

Primary: Identification of Brain Circuits Involved in a Task of Emotional Congruence (With fMRI) — -0.25; -0.21; 3.8; 0.2 arbitrary units of activation